Is SPRY or STOK more undervalued in 2026?

CirclFi compares ARS Pharmaceuticals, Inc. (SPRY) and Stoke Therapeutics, Inc. (STOK) using 13 institutional-grade valuation models. SPRY has a Quality of Company score of 4.7/10 while STOK scores 6.2/10.

Which is a better buy — SPRY or STOK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SPRY and STOK valuations compare?

SPRY at $9.40 and STOK at $31.61 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SPRY vs STOK Valuation Comparison 2026 — Intrinsic Value Analysis

SPRY

Biotechnology

ARS Pharmaceuticals, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$9.40

Last close

Models

8/13

Active

STOK

Biotechnology

Stoke Therapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$31.61

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	SPRY Fair Value	SPRY Upside	STOK Fair Value	STOK Upside
Bayesian DCF	Intrinsic	$2.27	-75.8%	$11.28	-64.3%
Earnings Power Value	Intrinsic	—	—	$6.33	-81.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.53	-83.7%	$1.47	-95.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SPRY vs STOK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SPRY vs STOK — Which Stock Is More Undervalued?

STOK scores higher with a 6.2/10 quality rating vs SPRY's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ARS Pharmaceuticals, Inc. (SPRY) and Stoke Therapeutics, Inc. (STOK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SPRY currently trades at $9.40 with a QOC of 4.7/10, while STOK trades at $31.61 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).